HC Wainwright Lowers Silence Therapeutics (NASDAQ:SLN) Price Target to $75.00

Silence Therapeutics (NASDAQ:SLNGet Free Report) had its target price cut by investment analysts at HC Wainwright from $80.00 to $75.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other equities research analysts have also commented on the company. Morgan Stanley reissued an “overweight” rating and set a $20.00 price target on shares of Silence Therapeutics in a research note on Monday, July 24th. Chardan Capital reiterated a “buy” rating and set a $26.00 target price on shares of Silence Therapeutics in a research report on Thursday, August 17th.

Read Our Latest Analysis on SLN

Silence Therapeutics Stock Down 0.1 %

SLN opened at $9.41 on Friday. The business has a 50 day simple moving average of $8.98 and a 200-day simple moving average of $7.25. Silence Therapeutics has a 12 month low of $4.55 and a 12 month high of $17.99. The stock has a market capitalization of $281.64 million, a P/E ratio of -6.49 and a beta of 0.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.21 and a quick ratio of 4.21.

Silence Therapeutics (NASDAQ:SLNGet Free Report) last announced its quarterly earnings results on Wednesday, August 16th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.23. The business had revenue of $11.40 million during the quarter, compared to the consensus estimate of $1.94 million. Silence Therapeutics had a negative net margin of 151.43% and a negative return on equity of 248.49%. On average, equities analysts anticipate that Silence Therapeutics will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Silence Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its holdings in Silence Therapeutics by 27.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company’s stock valued at $18,350,000 after purchasing an additional 205,815 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Silence Therapeutics during the second quarter worth approximately $136,000. UBS Group AG grew its stake in Silence Therapeutics by 4.8% in the 4th quarter. UBS Group AG now owns 69,006 shares of the company’s stock worth $1,052,000 after acquiring an additional 3,191 shares during the period. Morgan Stanley raised its holdings in Silence Therapeutics by 36.0% in the 4th quarter. Morgan Stanley now owns 210,973 shares of the company’s stock valued at $3,217,000 after acquiring an additional 55,814 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Silence Therapeutics by 19.8% during the 4th quarter. Millennium Management LLC now owns 17,436 shares of the company’s stock worth $266,000 after purchasing an additional 2,879 shares during the period. Hedge funds and other institutional investors own 64.27% of the company’s stock.

About Silence Therapeutics

(Get Free Report)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver.

Further Reading

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.